N-Acetyl Cysteine (NAC): Benefits, Forms, Dosing, and Side Effects

N-acetyl cysteine (NAC), also known as acetylcysteine, is a synthetically modified form of the amino acid cysteine. First approved by the FDA in 1963 as a prescription antidote for acetaminophen overdose and a mucolytic for respiratory conditions, NAC has gained widespread popularity as a dietary supplement for its antioxidant, anti-inflammatory, and glutathione-boosting properties. In the body, NAC is converted to cysteine — the rate-limiting precursor for glutathione, the body's primary intracellular antioxidant. This comprehensive guide covers the evidence for NAC across respiratory health, mental health, cardiovascular protection, aging, and more, along with recommended dosing, safety considerations, and drug interactions.

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Overview

N-acetyl cysteine (NAC), also known as acetylcysteine, is a synthetically modified form of the amino acid cysteine [1][2]. While cysteine occurs naturally in protein-rich foods such as meat, eggs, dairy, legumes, and seeds, NAC itself does not occur naturally in food [1][3]. In the body, NAC is deacetylated to release free cysteine, which serves as the rate-limiting substrate for the synthesis of glutathione (GSH) — the body's primary intracellular antioxidant [1][2][4]. Glutathione is a tripeptide comprising cysteine, glutamate, and glycine that reduces hydrogen peroxide and lipid hydroperoxides, maintains cellular redox balance, and supports detoxification pathways [2][4].

NAC is not an essential nutrient. There is no recommended daily allowance, and it is not classified as a vitamin or mineral [1]. However, NAC has a long history of clinical use: it was first approved by the U.S. Food and Drug Administration (FDA) in 1963 as a prescription medication for acetaminophen (paracetamol) overdose and as a mucolytic agent for respiratory conditions [5][6]. More recently, it has gained popularity as a dietary supplement promoted for its antioxidant, anti-inflammatory, and glutathione-boosting properties.

NAC's primary mechanism of action is through replenishment of intracellular glutathione stores [1][2]. Glutathione levels decline with age, chronic disease, and oxidative stress, contributing to cellular vulnerability [7]. By providing cysteine — the amino acid that limits glutathione synthesis — NAC indirectly supports the antioxidant defense system. NAC also exerts direct antioxidant effects through its free sulfhydryl (thiol) group, which can scavenge reactive oxygen species (ROS) [2][4]. Additionally, NAC modulates glutamate signaling through the cystine-glutamate antiporter, a mechanism relevant to its psychiatric applications [5][8].

The regulatory status of NAC as a dietary supplement has been contentious. In July 2020, the FDA issued warning letters asserting that NAC did not meet the definition of a dietary supplement because it was approved as a drug prior to being marketed as a supplement [6]. This led to the removal of NAC supplements from Amazon and other retailers. However, in April 2022, the FDA published draft guidance indicating it was considering permitting NAC as a dietary supplement, noting that its initial safety review had not revealed concerns regarding supplemental use [6]. The FDA's enforcement discretion policy, finalized in August 2022, allows the continued sale of NAC products marketed before October 2020, provided they do not make unauthorized disease claims [6]. As of 2025, full rulemaking remains pending, but NAC supplements are widely available from most retailers [6].

Forms and Bioavailability

Standard NAC (Free Form)

The vast majority of NAC supplements contain "free form" NAC — meaning the NAC molecule is not bound to a salt or stabilizer [1]. This is the form used in virtually all clinical trials. Supplement Facts panels may explicitly list "free form" after N-acetyl cysteine, but even products that do not state this designation typically contain the same free-form compound [1]. NAC is quite chemically stable and does not require special formulation for shelf life.

Oral Bioavailability

NAC has relatively low oral bioavailability. An animal study in rats measured oral bioavailability at approximately 4.8%, largely due to extensive first-pass hepatic metabolism where NAC is deacetylated to cysteine before reaching systemic circulation [9]. However, this low systemic bioavailability does not necessarily diminish its effectiveness, because the primary therapeutic target — glutathione synthesis — occurs predominantly in the liver and gut, which are the first tissues to encounter orally ingested NAC [2][5]. Clinical trials consistently demonstrate that oral NAC at doses of 600-2,400 mg/day increases blood and tissue glutathione levels, confirming functional efficacy despite limited systemic bioavailability [1][7].

NACET (N-Acetyl Cysteine Ethyl Ester)

Some products contain NAC in an ethyl ester form known as N-acetyl cysteine ethyl ester (NACET), marketed as being "20x more bioavailable than NAC." This claim is based on an animal study in rats that showed NACET bioavailability of 58.5% compared to 4.8% for standard NAC [9]. However, there do not appear to be similar bioavailability studies in humans [1]. Until human pharmacokinetic data confirm this advantage, the clinical relevance of the higher animal bioavailability is uncertain.

GlyNAC (Glycine + NAC)

GlyNAC is a combination supplement providing both NAC and glycine — the two amino acids (alongside glutamate) that constitute glutathione. The rationale is that both cysteine and glycine decline with age, and supplementing both precursors together may be more effective at restoring glutathione levels than NAC alone [7][10]. Preliminary clinical studies have used very high doses of GlyNAC (approximately 9 grams each of NAC and glycine daily) and reported improvements in multiple aging biomarkers [7][10][11]. However, these studies have been small, conducted by the same research group, and lack rigorous placebo-controlled statistical comparisons. Whether GlyNAC is meaningfully superior to NAC alone at equivalent doses remains unestablished.

Delivery Forms and Storage

NAC is available as capsules, tablets, effervescent tablets, and powder. Several clinical trials have used effervescent tablet formulations dissolved in water [1][12][13]. NAC capsules appear to be more stable than powder during long-term storage [14]. A laboratory study found no significant degradation of NAC gelatin capsules stored for 421 days (approximately 14 months) at ambient humidity regardless of temperature (35-104 degrees F), or at high humidity (75%) combined with low to room temperature. However, at high temperature (104 degrees F) combined with high humidity, 30-40% of NAC was lost after 421 days, and the physical integrity of the gelatin capsule was visibly compromised [14].

NAC powder should be stored in a closed container in a cool, dry place — away from excessive heat or moisture. Refrigeration is not necessary and could expose the powder to moisture once the container has been opened [1]. A slight sulfur smell (resembling cooked eggs) is common with NAC products and does not indicate significant spoilage or loss of NAC [1]. The odor results from oxidation of a small portion of NAC producing hydrogen sulfide. If NAC capsules appear physically deformed or misshapen, however, significant degradation has likely occurred [14]. Over longer storage periods, small amounts of NAC may degrade into di-NAC, a compound that is not known to be harmful and has shown preliminary anti-atherosclerotic effects in early research [15].

Evidence for Benefits

Acetaminophen Overdose and Liver Protection

NAC is the FDA-approved standard-of-care antidote for acetaminophen (Tylenol) poisoning [5][6]. During acetaminophen overdose, the toxic metabolite NAPQI (N-acetyl-p-benzoquinone imine) depletes hepatic glutathione stores, leading to centrilobular liver necrosis. NAC restores glutathione levels, enabling NAPQI detoxification [5][16]. Intravenous NAC achieves near-100% prevention of liver injury when initiated within 8 hours of ingestion [5][16].

Standard IV protocols involve a loading dose of 150 mg/kg followed by maintenance infusions over 21 hours [5][16]. The FDA-approved oral regimen consists of a 140 mg/kg loading dose followed by 70 mg/kg every 4 hours for 17 doses [16]. A small study in people with advanced cancer found that intravenous NAC taken within 8 hours of very high doses of acetaminophen appeared to protect the liver [17]. Preliminary animal studies suggest that NAC taken concurrently with large doses of acetaminophen may help protect the liver from acetaminophen-induced damage and may increase the anti-inflammatory effects of acetaminophen [18][19], but no human studies have evaluated this specific concurrent use.

Important caveat: NAC is frequently promoted as a general "liver support" supplement based on its role in acetaminophen poisoning. However, a general liver-protectant effect beyond acetaminophen toxicity has not been established in human studies [1].

Chronic Bronchitis and COPD

NAC's mucolytic properties — its ability to cleave disulfide bonds in mucoproteins, reducing mucus viscosity — underpin its FDA-approved use in respiratory conditions [5][20]. Oral NAC at 600-1,200 mg daily has demonstrated efficacy in reducing exacerbation frequency in chronic bronchitis and COPD [5][20].

An analysis of eight clinical trials found that 400-600 mg of NAC daily for 3 to 6 months significantly reduced exacerbations of chronic bronchitis [21]. In a separate clinical study, COPD patients who received 600 mg of NAC daily in addition to standard treatment medications for 6 months had significantly fewer flare-ups than those receiving medication alone [22]. Long-term use of up to 1,200 mg/day for respiratory conditions is generally well tolerated, with adverse effects primarily limited to mild gastrointestinal upset or bronchospasm in nebulized form [5][20].

Influenza and Immune Function

One placebo-controlled clinical study found that 600 mg of NAC taken twice daily during flu season (October through April) did not prevent influenza infection but significantly reduced symptom severity. Among individuals taking NAC who became infected, only 25% developed symptoms compared to 79% in the placebo group [23].

A small study among postmenopausal women in Brazil found that 600 mg of NAC taken as an effervescent tablet daily at bedtime for four months increased natural killer (NK) cell activity and improved other measures of immune function compared to baseline. However, the study was not placebo-controlled and did not report actual illness occurrence [24]. NAC supplementation has also been reported to restore NK cell activity in individuals with HIV [25]. Despite these findings, there is not sufficient evidence to conclude that NAC supplementation "boosts" the immune system to the degree that it reliably reduces illness occurrence in the general population [1].

COVID-19

There is no evidence that NAC supplementation can prevent COVID-19 [1]. However, a study in Greece among 82 adults (average age 63) hospitalized with moderate or severe COVID-19 pneumonia found that 600 mg of NAC given twice daily (as granules dissolved in water) in addition to standard care for 14 days significantly decreased progression to severe respiratory failure requiring mechanical ventilation [26]. Two of 42 patients (4.7%) given NAC required mechanical ventilation within 14 days versus 12 of 40 patients (30%) receiving standard care alone. At 28 days, 2 patients (4.7%) in the NAC group died compared to 12 patients (30%) in the standard care group [26].

However, a larger systematic review of 7 RCTs (n=651) found no statistically significant mortality benefit (RR 0.94, 95% CI 0.68-1.30) or increase in ventilator-free days with NAC treatment for COVID-19 [27]. This illustrates how mechanistic plausibility did not consistently translate to clinical benefit across multiple studies.

Mental Health: Schizophrenia

NAC has been studied as an adjunctive treatment in schizophrenia, based on the hypothesis that oxidative stress and glutamate dysregulation contribute to the disorder [5][8]. A randomized, double-blind clinical trial found that 1,000 mg of NAC taken twice daily (2,000 mg/day total) in addition to maintenance antipsychotic medications significantly improved scores on symptom scales and decreased akathisia (restlessness) compared to medications plus placebo [28]. A subsequent study in patients with chronic schizophrenia taking risperidone found that NAC supplementation (up to 2,000 mg per day) significantly improved negative symptom scores compared to risperidone plus placebo [29].

However, results have been inconsistent across larger trials. A 2025 study found that NAC lacked efficacy for core symptoms of schizophrenia, highlighting the need for biomarker-driven patient selection to identify responsive subgroups [5][30]. Meta-analyses emphasize heterogeneous outcomes, with effect sizes often small (Cohen's d less than 0.5) [5][8].

Mental Health: Compulsive Behaviors

Several small but well-controlled clinical studies indicate NAC may reduce compulsive behaviors, possibly by modulating glutamate concentrations in the nucleus accumbens [31].

Skin picking (excoriation disorder): In a study of adults with excoriation disorder, 1,200 to 3,000 mg of NAC per day (escalating over 12 weeks) along with existing medications was compared to placebo. The NAC group showed significant improvements: 47% were rated "much or very much improved" versus 19% of the placebo group. Obsessive-compulsive excoriation scale scores decreased from 18.9 to 11.5 in the NAC group versus 17.9 to 14.1 in the placebo group. The researchers noted that benefits appeared primarily in reducing urges and cravings to pick rather than the actual behavior [31].

Trichotillomania (compulsive hair-pulling): A study found that 1,200 to 2,400 mg of NAC daily for 12 weeks significantly reduced hair-pulling symptoms compared to placebo [32]. Pathological gambling: Daily supplementation with approximately 1,500 mg of NAC improved measures of obsessive-compulsive behavior in people with pathological gambling [33].

Mental Health: Bipolar Depression, OCD, and Autism

Meta-analyses indicate that NAC as an adjunct to standard treatments produces modest reductions in depressive symptoms in bipolar depression, potentially linked to its role in normalizing brain redox balance [5][8]. However, evidence for unipolar major depression remains preliminary and not uniformly supportive [5].

For obsessive-compulsive disorder (OCD), open-label and small randomized trials have reported symptom severity decreases of up to 30-40% at doses of 2,400-3,000 mg/day, attributed to glutamate modulation in cortico-striatal circuits [5]. However, a 2024 meta-analysis of 10 RCTs (n=413) found that benefits were confined to adjunctive therapy at doses of 2,000 mg/day or higher, with no superiority over placebo for monotherapy [34]. A pilot randomized trial (n=33 children) of 900-2,700 mg/day NAC for autism spectrum disorder found a 25% reduction in irritability scores on the Aberrant Behavior Checklist compared to placebo [35].

Substance Use Disorders

NAC has been tested for cocaine, cannabis, and nicotine dependence based on its ability to restore extracellular glutamate homeostasis through the cystine-glutamate antiporter [5][36]. A meta-analysis reported modest overall craving reductions (Hedges' g approximately -0.48 across 12 RCTs, n=681) with high heterogeneity (I-squared greater than 70%) and publication bias risks [37]. Phase II trials have often failed to demonstrate sustained abstinence benefits, and youth cannabis trials showed null effects [37][38]. The evidence remains insufficient to recommend NAC as a standard treatment for addiction.

Cardiovascular Disease

Cardiovascular events in renal failure: In patients with end-stage renal failure, 600 mg of NAC taken twice daily (1,200 mg/day) reduced the incidence of cardiovascular events — including stroke and heart attack — by 40% compared to placebo, although it did not reduce overall mortality [39].

Homocysteine reduction: NAC has been shown to lower homocysteine levels. In a small clinical study, effervescent tablets containing 2,000 mg of NAC taken twice daily (4,000 mg/day total) for two weeks lowered homocysteine levels by 45% compared to placebo [12].

Angina and myocardial infarction: NAC has been tried in combination with nitroglycerin (both given intravenously) to treat angina and in people with acute myocardial infarction, yielding some positive results [40][41]. Kidney protection during angiography: NAC has been used to prevent contrast-induced kidney injury, but a large study found that 1,200 mg of NAC given before and after angiography provided no benefit compared to placebo [42].

Fertility (PCOS)

In women being treated for infertility associated with polycystic ovary syndrome (PCOS), taking 1,200 mg of NAC daily along with the fertility drug clomiphene citrate significantly increased rates of ovulation and pregnancy compared to treatment with clomiphene citrate alone [43].

Heavy Metal Detoxification

Laboratory and animal studies suggest that NAC may have a chelating effect by binding to heavy metals such as lead, cadmium, and mercury [44]. A study in Poland among 171 men with elevated blood lead levels from occupational exposure found that 200-800 mg of oral NAC daily for three months reduced average blood lead levels from approximately 48 mcg/dL to 42 mcg/dL — a statistically significant decrease compared to a control group. However, the effect was no greater at doses above 200 mg, and final lead levels remained very high [45]. A study of pregnant women with elevated lead levels given 400 mg of NAC daily for six weeks showed a decrease from 38 mcg/dL to 18 mcg/dL [46]. Neither study included a true placebo group [1].

Breast Pain (Cyclical Fibrocystic)

A study among 64 women with moderate to severe cyclical fibrocystic breast pain found that 600 mg of NAC daily for 12 weeks modestly reduced self-reported breast pain on the first day of the menstrual cycle compared to placebo (a decrease of 2.7 points versus no decrease on a scale of 1 to 10). NAC also increased blood glutathione levels and reduced C-reactive protein (CRP), a marker of inflammation [47].

Sjogren's Syndrome

A small double-blind clinical trial found that 200 mg of NAC taken three times daily (600 mg/day) improved eye-related symptoms such as soreness and irritation in people with Sjogren's syndrome [48].

Ulcerative Colitis

A study among 168 people with ulcerative colitis in remission found that taking 400 mg of NAC twice daily (800 mg/day) for 16 weeks while slowly discontinuing prednisolone helped maintain remission by week 22. Relapse occurred in only 7% of the NAC group compared to 22% in the placebo group [49].

Parkinson's Disease

People with Parkinson's disease given 500 mg of NAC orally daily in addition to approximately 3,500 mg of NAC intravenously weekly for three months showed significantly improved symptoms and slightly increased dopamine transporter binding compared to standard care in a small study [50]. However, the study was not placebo-controlled, and the oral NAC contribution is likely much smaller than the IV component.

Progressive Myoclonus Epilepsy

High doses of NAC (4,000-6,000 mg daily) were reported to reduce myoclonus in four patients with progressive myoclonus epilepsy when added to a regimen of vitamin E, selenium, riboflavin, zinc, and magnesium [51]. This is a very small case series and cannot establish causation.

Hearing Loss (Noise-Induced)

Results are mixed. A study of 53 workers with occupational noise exposure found that 1,200 mg of NAC daily for 14 days modestly reduced temporary noise-induced hearing loss from high-frequency noise, with the effect significant only in individuals with genotypes increasing susceptibility to oxidative damage [52]. However, a larger study of 566 Marine Corps recruits found that 1,800-2,700 mg of NAC daily during 16 days of weapons training did not reduce hearing loss or prevent tinnitus compared to placebo [53].

Acne

A small study found that 1,200 mg/day of oral NAC for 8 weeks significantly reduced inflammatory acne lesions compared to placebo [54]. Topical 5% NAC gel applied twice daily for 8 weeks reduced comedones by 37-46% compared to 23% with placebo [55]. However, a meta-analysis of 8 studies in 910 women with PCOS found that 1,200-1,800 mg/day of NAC for 2-12 months did not improve acne [56].

Aging and Longevity

In animal models, NAC increased lifespan in male mice (but not female mice), though this effect may have been mediated by reduced food intake [57].

GlyNAC (Glycine + NAC) for aging: A study among 8 elderly people found that GlyNAC providing approximately 9.4 grams of NAC and 7 grams of glycine daily for 24 weeks improved glutathione deficiency, oxidative stress, inflammation, insulin resistance, and cognitive function compared to baseline, with improvements declining when supplementation stopped [7]. A subsequent study among 23 older adults using similar doses for 16 weeks found glutathione increased 164-225%, oxidative stress reduced by 72%, blood pressure decreased by 8 mmHg, gait speed improved 18%, and grip strength increased 14% [11]. Both studies lacked rigorous placebo-controlled comparisons [1][7][11].

Nasal Congestion and Sinusitis

NAC can thin nasal mucus in laboratory settings [58] and increase nasal airflow when inhaled with a decongestant [59]. However, there is little clinical evidence that oral supplementation reduces nasal mucus [1]. A Cochrane review of aerosolized NAC for cystic fibrosis concluded that studies did not provide evidence of benefit [60].

Lung Cancer Concern (Preclinical)

A study in aging mice found that NAC promoted lung cancer formation in 2 of 15 mice, and 7 of 14 mice lacking a protective gene developed lung cancer [61]. Separate data suggest NAC may accelerate metastasis in established lung cancers [62]. Researchers cautioned that NAC treatment in smokers or COPD patients should be considered with great caution [61]. This has not been observed in humans.

Recommended Dosing

NAC is not an essential nutrient and has no established recommended daily allowance [1]. The dose used in clinical trials has ranged from 600 mg to 3,000 mg per day, typically divided into two or three servings [1].

Dosing by Indication

Condition	Dose (per day)	Duration	Notes
General antioxidant / glutathione support	600-1,200 mg	Ongoing	Typical range, divided 1-2 doses [1]
Chronic bronchitis / COPD	400-1,200 mg	3-6 months	600 mg/day most common [21][22]
Influenza symptom reduction	1,200 mg (600 mg twice daily)	Flu season	Reduced symptoms, not infection [23]
Schizophrenia (adjunctive)	2,000 mg (1,000 mg twice daily)	8-24 weeks	Added to existing medications [28][29]
Compulsive behaviors	1,200-3,000 mg	12 weeks	Escalating dose [31][32]
Pathological gambling	~1,500 mg	Variable	Adjunctive use [33]
PCOS / fertility	1,200 mg	Variable	With clomiphene citrate [43]
Homocysteine reduction	4,000 mg (2,000 mg twice daily)	2 weeks	High dose; short-term study [12]
CV events (renal failure)	1,200 mg (600 mg twice daily)	Ongoing	End-stage renal disease [39]
Ulcerative colitis (remission)	800 mg (400 mg twice daily)	16 weeks	Adjunct during steroid taper [49]
GlyNAC (anti-aging)	~9,000 mg NAC + ~9,000 mg glycine	16-24 weeks	Very high dose; limited evidence [7][11]
Heavy metal (lead) reduction	200-800 mg	3 months	No benefit above 200 mg [45]
Acne (oral)	1,200 mg (600 mg twice daily)	8 weeks	Limited evidence [54]
Hearing loss prevention	1,200-2,700 mg	14-16 days	Mixed results [52][53]

How to Take NAC

NAC may be taken with or without food [1]. However, higher doses can cause stomach upset (likely due to NAC's acidity), in which case taking it with food may help [1]. Splitting doses (e.g., twice daily) is common in clinical trials and may improve tolerability at higher daily intakes.

Safety and Side Effects

General Tolerability

NAC is generally well tolerated at typical supplemental doses (600-1,200 mg/day) [1][5]. The overall adverse event rate at doses of 1,200-2,400 mg/day is less than 5%, with nausea being the most common complaint [5][63].

Common Side Effects

At higher doses (1,200 mg/day or more), some people experience [1][5]:

• Headache
• Nausea
• Abdominal pain
• Vomiting
• Constipation
• Diarrhea

These symptoms may relate in part to the acidity of NAC [1].

Body Odor

A study found that approximately 6% of people taking 1,200 mg of NAC daily reported body odor during treatment [64]. The researchers attributed this to the release of hydrogen sulfide in the gastrointestinal tract from NAC decomposition. This mechanism may also contribute to other gastrointestinal symptoms [64].

Blood Clotting

NAC may slow blood clotting. It has demonstrated anticoagulant and platelet-inhibiting properties in laboratory research [65]. Clinical research has shown that high doses of NAC given intravenously can decrease prothrombin time and increase blood loss during surgery compared to placebo [66]. NAC should not be taken with blood thinners or by people with bleeding disorders except under physician supervision.

Asthma

NAC has been alleged to worsen asthma symptoms [31]. People with asthma should exercise caution and consult their physician before supplementation.

Blood Test Interference

NAC can interfere with blood tests for cholesterol (including HDL) and uric acid, showing falsely low results [67][68]. This effect is mainly of concern with large doses given within 12 hours before blood draw. Typical oral supplemental doses are very unlikely to cause interference, but avoiding NAC within a day before blood tests eliminates any chance of interference [1].

Pregnancy and Lactation

Women who are pregnant or nursing should not take NAC unless directed by their physician [1]. While IV NAC is used during pregnancy for acetaminophen overdose, the safety of chronic oral supplementation in pregnancy has not been established [5].

Lung Cancer Concern (Preclinical)

Long-term NAC use promoted lung cancer in aging mice, particularly those with impaired oxidative stress defenses [61]. Separate preclinical data suggest NAC may promote metastasis in established lung cancers [62]. This has not been observed in humans, but smokers and COPD patients should discuss NAC use with their physician [1][61].

Sulfonamide Allergy

Although NAC is a sulfur-containing compound, being allergic to sulfonamide antibiotics or other "sulfa drugs" does not make one sensitive to NAC due to chemical differences [69].

Contaminated Products

An NAC product (TauriNAC by Planetary Biosciences) was found to provide 16,000 mcg of iodide — nearly 15 times the Tolerable Upper Intake Level — in a recommended serving. A woman with cystic fibrosis developed hypothyroidism after taking it, with thyroid tests normalizing after discontinuation and worsening upon resumption [70]. This underscores the importance of purchasing NAC from reputable manufacturers.

Drug Interactions

Drug / Class	Interaction	Clinical Recommendation
Nitroglycerin	Severe headaches and unsafe blood pressure drops	Do not take with NAC except under physician supervision [1]
Blood thinners (anticoagulants)	NAC has anticoagulant and platelet-inhibiting properties	Do not take with blood thinners except under physician supervision [65][66]
Activated charcoal	Charcoal may adsorb orally administered NAC	Separate by 1-2 hours [16]
Antidiabetic medications	NAC may lower blood glucose	Monitor blood sugar carefully [63]
Immunosuppressants	Theoretical immune-modulating interaction	Consult physician before combining

Dietary Sources

NAC does not occur naturally in food [1]. However, the amino acid cysteine — which NAC provides after deacetylation — is found in protein-rich foods. The body also synthesizes cysteine from the essential amino acid methionine through the transsulfuration pathway in the liver [2][3].

Cysteine-Rich Foods

Food	Serving	Approximate Cysteine (mg)
Beef liver	1 slice (100g)	~390
Pork loin	100g	~300-400
Chicken breast	100g	~250-350
Eggs	2 large	~200-300
Cheese (cheddar)	100g	~200-300
Salmon / Tuna	100g	~200-300
Low-fat yogurt	1 cup	~150-200
Lentils (cooked)	1 cup	~140-200
Soybeans (cooked)	1 cup	~140-200
Oatmeal (cooked)	1 cup	~140-160
Sunflower seeds	1 oz (28g)	~100-150

Sources: USDA FoodData Central; Grokipedia [3][71].

Practical Notes

• The daily cysteine requirement is approximately 4.1 mg/kg body weight (about 290 mg for a 70 kg adult), which is typically met through normal protein intake alongside methionine [3].
• Animal products provide more complete amino acid profiles and higher cysteine density per serving than plant sources [3].
• Adequate dietary protein should supply sufficient cysteine for normal glutathione synthesis in healthy individuals. However, glutathione levels decline with age, chronic illness, and oxidative stress — situations where supplemental NAC may provide additional benefit [7][10].
• Methionine from the diet can be converted to cysteine through the transsulfuration pathway, but this pathway has limited capacity and depends on adequate vitamin B6 (pyridoxal phosphate) as a cofactor [2][3].

References

1. ConsumerLab. "N-Acetyl Cysteine (NAC) Supplements Review." Accessed 2025. https://www.consumerlab.com/reviews/n-acetyl-cysteine-nac-supplements/n-acetyl-cysteine/

2. Grokipedia. "Cysteine." https://grokipedia.com/page/Cysteine

3. USDA FoodData Central. https://fdc.nal.usda.gov/

4. Samuni Y, Goldstein S, Dean OM, et al. "The chemistry and biological activities of N-acetylcysteine." Biochim Biophys Acta. 2013;1830(8):4117-4129. https://doi.org/10.1016/j.bbagen.2013.04.016

5. N-Acetylcysteine. StatPearls. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK537183/

6. U.S. FDA. "Policy Regarding N-acetyl-L-cysteine; Guidance for Industry." August 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-regarding-n-acetyl-l-cysteine-guidance-industry

7. Kumar P, Liu C, Hsu JW, et al. "GlyNAC supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition." Clin Transl Med. 2021;11(3):e372. https://doi.org/10.1002/ctm2.372

8. Berk M, Malhi GS, Gray LJ, Dean OM. "The promise of N-acetylcysteine in neuropsychiatry." Trends Pharmacol Sci. 2013;34(3):167-177. https://doi.org/10.1016/j.tips.2013.01.001

9. Giustarini D, et al. "N-acetylcysteine ethyl ester (NACET): a novel lipophilic cell-permeable cysteine derivative." Biochem Pharmacol. 2012;84(11):1522-1533. https://doi.org/10.1016/j.bcp.2012.09.003

10. Sekhar RV, et al. "Deficient synthesis of glutathione underlies oxidative stress in aging." Am J Clin Nutr. 2011;94(3):847-853. https://doi.org/10.3945/ajcn.110.003483

11. Kumar P, Osahon OW, Sekhar RV. "GlyNAC Supplementation in Old Mice Improves Brain Glutathione Deficiency." J Gerontol A Biol Sci Med Sci. 2022;77(5):931-941. https://doi.org/10.1093/gerona/glab379

12. Wiklund O, et al. "N-acetylcysteine treatment lowers plasma homocysteine." Atherosclerosis. 1996;119(1):99-106. https://doi.org/10.1016/0021-9150(95)05661-2

13. Arranz L, et al. "N-acetylcysteine improves immune function in postmenopausal women." Free Radic Biol Med. 2008;45(9):1252-1262. https://doi.org/10.1016/j.freeradbiomed.2008.07.014

14. To D, Bhatt D, Bhatt S. "Stability of N-acetylcysteine in commonly used gelatin capsule formulations." J Pharm Pract. 2008;21(4):284-289.

15. Pettersson K, et al. "Di-N-acetylcysteine as a modulator of atherosclerosis." Cardiovasc Drug Rev. 2003;21(2):157-168.

16. Acetaminophen Toxicity Treatment and Management. Medscape/eMedicine. https://emedicine.medscape.com/article/820200-treatment

17. Kobrinsky NL, et al. "Treatment of advanced malignancies with high-dose acetaminophen and N-acetylcysteine rescue." Cancer Invest. 1996;14(3):202-210. https://doi.org/10.3109/07357909609012140

18. Owumi SE, Dim UJ. "Biochemical and histological modulations of N-acetylcysteine on acetaminophen-induced hepatorenal toxicity." Drug Dev Res. 2015;76(5):251-258.

19. Qiu Y, et al. "Identification of hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice." Vet Immunol Immunopathol. 2013.

20. Cazzola M, et al. "Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis." Eur Respir Rev. 2015;24(137):451-461. https://doi.org/10.1183/16000617.00002215

21. Grandjean EM, et al. "Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease." Clin Ther. 2000;22(2):209-221. https://doi.org/10.1016/S0149-2918(00)80090-4

22. Pela R, et al. "N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD." Respiration. 1999;66(6):495-500. https://doi.org/10.1159/000029447

23. De Flora S, et al. "Attenuation of influenza-like symptomatology with long-term N-acetylcysteine treatment." Eur Respir J. 1997;10(7):1535-1541. https://doi.org/10.1183/09031936.97.10071535

24. Arranz L, et al. "N-acetylcysteine improves immune function in postmenopausal women." Free Radic Biol Med. 2008;45(9):1252-1262. https://doi.org/10.1016/j.freeradbiomed.2008.07.014

25. Droge W, Breitkreutz R. "N-acetyl-cysteine in the therapy of HIV-positive patients." Proc Nutr Soc. 2000;59(4):595-600.

26. Assimakopoulos SF, et al. "N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia." Infect Dis (Lond). 2021;53(11):847-854. https://doi.org/10.1080/23744235.2021.1945675

27. Akhter J, et al. "Clinical efficacy of N-acetylcysteine for COVID-19: a systematic review and meta-analysis." iScience. 2024. https://doi.org/10.1016/j.isci.2024.110573

28. Berk M, et al. "N-acetyl cysteine as a glutathione precursor for schizophrenia." Biol Psychiatry. 2008;64(5):361-368. https://doi.org/10.1016/j.biopsych.2008.03.004

29. Farokhnia M, et al. "N-acetylcysteine as adjunct to risperidone for negative symptoms in chronic schizophrenia." Clin Neuropharmacol. 2013;36(6):185-192. https://doi.org/10.1097/WNF.0000000000000001

30. Neill JC, et al. "Antipsychotic augmentation with N-acetylcysteine for patients with schizophrenia." J Clin Psychiatry. 2025.

31. Grant JE, et al. "N-Acetylcysteine in the Treatment of Excoriation Disorder." JAMA Psychiatry. 2016;73(5):490-496. https://doi.org/10.1001/jamapsychiatry.2016.0060

32. Grant JE, et al. "N-acetylcysteine in the treatment of trichotillomania." Arch Gen Psychiatry. 2009;66(7):756-763. https://doi.org/10.1001/archgenpsychiatry.2009.60

33. Grant JE, et al. "N-acetyl cysteine in the treatment of pathological gambling: a pilot study." Biol Psychiatry. 2007;62(6):652-657. https://doi.org/10.1016/j.biopsych.2006.11.021

34. Gadallah AA, et al. "N-Acetyl Cysteine in the Treatment of OCD: a systematic review and meta-analysis." Annals Gen Psychiatry. 2024.

35. Hardan AY, et al. "A randomized controlled pilot trial of oral N-acetylcysteine in children with autism." Biol Psychiatry. 2012;71(11):956-961. https://doi.org/10.1016/j.biopsych.2012.01.014

36. Squeglia LM, et al. "N-acetylcysteine: A potential treatment for substance use disorders." Curr Psychiatry. 2018.

37. Duailibi MS, et al. "N-acetylcysteine in substance use disorders: a systematic review." Am J Addict. 2018.

38. Gray KM, et al. "N-acetylcysteine for youth cannabis use disorder." Nat Med. 2021.

39. Tepel M, et al. "The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure." Circulation. 2003;107(7):992-995. https://doi.org/10.1161/01.CIR.0000050628.11305.30

40. Pasupathy S, et al. "Early use of N-acetylcysteine with nitrate therapy in STEMI." Circulation. 2017;136(10):894-903. https://doi.org/10.1161/CIRCULATIONAHA.117.027575

41. Horowitz JD, et al. "Potentiation of cardiovascular effects of nitroglycerin by N-acetylcysteine." Eur Heart J. 1988;9(4):411-418.

42. Weisbord SD, et al. "Outcomes after angiography with sodium bicarbonate and acetylcysteine." N Engl J Med. 2017;378(7):603-614. https://doi.org/10.1056/NEJMoa1710933

43. Rizk AY, et al. "N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in PCOS." Fertil Steril. 2005;83(2):367-370. https://doi.org/10.1016/j.fertnstert.2004.07.948

44. Samuni Y, et al. "The chemistry and biological activities of N-acetylcysteine." Biochim Biophys Acta. 2013;1830(8):4117-4129. https://doi.org/10.1016/j.bbagen.2013.04.016

45. Kasperczyk S, et al. "Effect of N-acetylcysteine on antioxidant enzymes in lead-exposed workers." Toxicol Ind Health. 2015;31(12):1154-1164.

46. Motawei SM, et al. "Lead level in pregnant women and protective role of N-acetylcysteine." Obstet Gynecol Cases Rev. 2018;5:120.

47. Kashi AA, et al. "Effect of oral N-acetyl cysteine on fibrocystic breast pain." Surg Open Sci. 2022;10:69-73.

48. Walters MT, et al. "A double-blind, cross-over, study of oral N-acetylcysteine in Sjogren's syndrome." Scand J Rheumatol Suppl. 1986;61:253-258.

49. Shirazi KM, et al. "Effect of N-acetylcysteine on relapse of ulcerative colitis." Clin Res Hepatol Gastroenterol. 2020;44(4):495-501.

50. Monti DA, et al. "N-Acetyl cysteine is associated with dopaminergic improvement in Parkinson's disease." Clin Pharmacol Ther. 2019;106(4):884-890. https://doi.org/10.1002/cpt.1548

51. Hurd RW, et al. "Treatment of four siblings with progressive myoclonus epilepsy with N-acetylcysteine." Neurology. 1996;47(5):1264-1268.

52. Lin CY, et al. "N-acetyl-cysteine against noise-induced temporary threshold shift." Hear Res. 2010;269(1-2):42-47. https://doi.org/10.1016/j.heares.2010.07.005

53. Kopke RD, et al. "NAC for noise: from the bench top to the clinic." Hear Res. 2015;226:114-125. https://doi.org/10.1016/j.heares.2005.10.006

54. Sahib AS, et al. "Effects of oral antioxidants on lesion counts in patients with papulopustular acne." J Clin Exp Dermatol Res. 2012;3:163.

55. Montes LF, et al. "N-acetylcysteine gel for mild acne." Skinmed. 2012;10(4):215-219.

56. Thakker D, et al. "N-acetylcysteine for polycystic ovary syndrome: a systematic review." Obstet Gynecol Int. 2015;2015:817849. https://doi.org/10.1155/2015/817849

57. Flurkey K, et al. "Life extension by diet restriction and N-acetyl-L-cysteine in genetically heterogeneous mice." J Gerontol A Biol Sci Med Sci. 2010;65A(12):1275-1284. https://doi.org/10.1093/gerona/glq155

58. Rhee CS, et al. "Effects of mucoactive agents on rheological properties of nasal mucus." Arch Otolaryngol Head Neck Surg. 1999;125(1):101-105.

59. Cogo R, et al. "N-acetylcysteine aerosol combined with xylometazoline on nasal mucociliary transport." Arzneimittelforschung. 1996;46(11):1047-1050.

60. Tam J, et al. "Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis." Cochrane Database Syst Rev. 2013;(7):CD007168. https://doi.org/10.1002/14651858.CD007168.pub3

61. Breau M, et al. "N-acetylcysteine protects from lung emphysema but induces lung adenocarcinoma in mice." JCI Insight. 2019;4(19):e127647. https://doi.org/10.1172/jci.insight.127647

62. Sayin VI, et al. "Antioxidants accelerate lung cancer progression in mice." Sci Transl Med. 2014;6(221):221ra15. https://doi.org/10.1126/scitranslmed.3007653

63. Mokhtari V, et al. "A review on various uses of N-acetyl cysteine." Cell J. 2017;19(1):11-17. https://doi.org/10.22074/cellj.2016.4872

64. Qi Q, et al. "Effect of N-acetylcysteine on exacerbations of bronchiectasis." Respir Res. 2019;20:73. https://doi.org/10.1186/s12931-019-1042-x

65. Nikbakht F, et al. "Anticoagulant and platelet inhibitory effects of N-acetylcysteine." Curr Clin Pharmacol. 2017;12(4):214-222.

66. Niemi TT, et al. "N-acetylcysteine on blood coagulation and platelet function during aortic aneurysm repair." Blood Coagul Fibrinolysis. 2006;17(1):29-34.

67. Beckman Coulter. "Instructions for Use." 2015.

68. Genzen JR, et al. "N-acetylcysteine interference of triacylglycerol/glycerol blanked assay." Clin Biochem. 2016;49(16-17):1283-1286.

69. ASCIA. "Sulfonamide Antibiotic Allergy." https://www.allergy.org.au/hp/drug-allergy/sulfonamide-antibiotic-allergy

70. Blount BC, et al. "Hypothyroidism associated with excessive iodide from a dietary supplement." JES. 2022;6(12):bvac155.

71. USDA FoodData Central. https://fdc.nal.usda.gov/